The nimml institute and nimmune biopharma announce publication of new mechanistic insights on the immunometabolic control of systemic lupus erythematosus in the journal of immunology

Blacksburg, va.--(business wire)--the nimml institute, (“nimml”), a 501 (c)(3) nonprofit research institute dedicated to the discovery of novel precision medicines for infectious and autoimmune diseases, today announced the publication of a seminal article that reports the mechanisms of therapeutic efficacy of nim-1324, an orally administered lancl2 agonist, in ameliorating the severity of systemic lupus erythematosus (sle) and addressing the unmet clinical needs of sle patients. these novel me.
SLE Ratings Summary
SLE Quant Ranking